Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Intima Bioscience Inc. is currently handling 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is being reviewed by 1 distinct examiner, which points to a very specific and focused prosecution pipeline. This concentration suggests that the company's current patenting activity is limited to a single key application or a very narrow technical field.
The prosecution is localized within 1 distinct art unit, meaning the technical scrutiny of the company's claims is centralized. JENNIFER SUZANNE SPENCE is the busiest examiner for the portfolio, currently overseeing 1 pending office action. Because she is the only examiner with an active case, the company's immediate progress at the USPTO is tied directly to her evaluation and feedback.
With 1 pending office action and 1 distinct examiner, the company does not face the complexity of managing multiple simultaneous legal challenges. The focus on 1 art unit allows for a specialized strategy that addresses the specific standards of that group. The role of JENNIFER SUZANNE SPENCE is critical, as her decisions on the 1 pending action will determine the short-term outcome for the company's patent portfolio in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048227 | COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE | SPENCE, JENNIFER SUZANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18048227 | COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE | SPENCE, JENNIFER SUZANNE | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18048227 | COMPOSITIONS AND METHODS OF GENERATING AN IMMUNE RESPONSE | SPENCE, JENNIFER SUZANNE | 1633 | §101§102§103 | Final Rejection | — | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial